These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24713311)

  • 1. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
    van Hasselt JGC; van Calsteren K; Heyns L; Han S; Mhallem Gziri M; Schellens JHM; Beijnen JH; Huitema ADR; Amant F
    Ann Oncol; 2014 Oct; 25(10):2059-2065. PubMed ID: 24713311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
    Janssen JM; Van Calsteren K; Dorlo TPC; Halaska MJ; Fruscio R; Ottevanger P; Schröder CP; Boere I; Witteveen PO; Painter RC; Bekkers R; Drochytek V; Beijnen JH; Huitema ADR; Amant FCH
    Clin Pharmacokinet; 2021 Jun; 60(6):775-784. PubMed ID: 33506375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.
    Janssen JM; Damoiseaux D; van Hasselt JGC; Amant FCH; van Calsteren K; Beijnen JH; Huitema ADR; Dorlo TPC
    Clin Pharmacokinet; 2023 Aug; 62(8):1157-1167. PubMed ID: 37351792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics.
    Berveiller P; Selleret L; Mir O
    Ann Oncol; 2014 Oct; 25(10):1869-1870. PubMed ID: 25125694
    [No Abstract]   [Full Text] [Related]  

  • 5. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer.
    Lunardi G; Venturini M; Vannozzi MO; Tolino G; Del ML; Bighin C; Schettini G; Esposito M
    Ann Oncol; 2002 Feb; 13(2):280-5. PubMed ID: 11886006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study.
    Van Calsteren K; Verbesselt R; Ottevanger N; Halaska M; Heyns L; Van Bree R; de Bruijn E; Chai D; Delforge M; Noens L; Renard V; Witteveen E; Rob L; de Hoon J; Amant F
    Acta Obstet Gynecol Scand; 2010 Oct; 89(10):1338-45. PubMed ID: 20846067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
    Esposito M; Venturini M; Vannozzi MO; Tolino G; Lunardi G; Garrone O; Angiolini C; Viale M; Bergaglio M; Del Mastro L; Rosso R
    J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
    Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
    Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
    Venturini M; Lunardi G; Del Mastro L; Vannozzi MO; Tolino G; Numico G; Viale M; Pastrone I; Angiolini C; Bertelli G; Straneo M; Rosso R; Esposito M
    J Clin Oncol; 2000 May; 18(10):2116-25. PubMed ID: 10811677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
    Sparano JA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
    Venturini M; Michelotti A; Papaldo P; Del Mastro L; Bergaglio M; Lionetto R; Lunardi G; Sguotti C; Frevola L; Donati S; Rosso R; Cognetti F
    Ann Oncol; 2001 Aug; 12(8):1097-106. PubMed ID: 11583191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.
    Hammann F; Gotta V; Conen K; Medinger M; Cesana P; Rochlitz C; Taegtmeyer AB
    Br J Clin Pharmacol; 2017 Apr; 83(4):927-930. PubMed ID: 27868228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of epirubicin and docetaxel in combination in rats.
    Sandström M; Simonsen LE; Freijs A; Karlsson MO
    Cancer Chemother Pharmacol; 1999; 44(6):469-74. PubMed ID: 10550567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions.
    Ceruti M; Tagini V; Recalenda V; Arpicco S; Cattel L; Airoldi M; Bumma C
    Farmaco; 1999; 54(11-12):733-9. PubMed ID: 10668172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profiles of doxorubicin in combination with taxanes.
    Holmes FA; Rowinsky EK
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):8-14. PubMed ID: 11552225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacology of the taxanes: implications of the differences.
    Gligorov J; Lotz JP
    Oncologist; 2004; 9 Suppl 2():3-8. PubMed ID: 15161985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
    Platel D; Pouna P; Bonoron-Adèle S; Robert J
    Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer.
    Syvanen K; Ekholm E; Anttila K; Salminen E
    Anticancer Res; 2003; 23(2C):1869-73. PubMed ID: 12820471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.